Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
Efficacy of Indobufen in the Treatment of Intermittent Claudication
The aim of this trial was to assess the activity of indobufen compared with placebo in peripheral occlusive arterial disease of the lower limbs of atheroscle rotic or diabetic origin . Fifty-two out patients were admitted to the r and omized , double-blind study and were given either an indobufen 200-mg tablet ( 28 sub jects ) or placebo ( 24 ) for six months . Painfree walking distance on a treadmill at a constant speed ( 4 km/h ) and slope ( 10 ° ) was assessed before and after three and six months ' treatment . The painfree walking distance before treatment with indobufen or placebo averaged 153 ± 23.02 ( mean ± SE ) and 199 ± 30.58 ( mean ± SE ) meters respectively . After six months ' treatment with active drug or placebo , this parameter reached 610 ± 115.36 ( p < 0.01 ) and 243 ± 32.49 ( p > 0.05 ) meters respec tively . The difference between the two treatments was statistically significant in favor of indobufen ( p < 0.01 Dunn 's test )
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .